In contrast, for SAVI patients, STING antagonists are the therapeutics of choice, although it is not yet known if one compound might be capable of blocking, to the same extent, all (hyperactivated) STING mutants that have been identified so far. Here, STING1 is linked to STING-associated vasculopathy with onset in infancy.